News | Cardiovascular Ultrasound | September 14, 2021

FDA Clears Fully Automated Cardiac Ultrasound Solution to Measure 2D and Doppler

The artificial intelligence received external validation at Brigham and Women's Hospital of Harvard Medical School has received U.S. Food and Drug Administration (FDA) clearance for its artificial intelligence (AI) Us2.v1 software, a completely automated decision support tool for echocardiography.

September 14, 2021 –, a Singapore-based medtech firm backed by Sequoia India and EDBI, has received U.S. Food and Drug Administration (FDA) clearance for Us2.v1, a completely automated decision support tool for echocardiography.

After multiple trials with global pharmaceutical partners, and a validation study at the Brigham & Women’s Hospital, announced the artificial intelligence (AI) software is now available for clinical use in the United States. 

Us2.v1 is an automated clinical workflow solution that recognizes and analyzes 2-dimensional and Doppler echo images for comprehensive cardiac ultrasound measurements needed for the diagnosis, prediction and prognosis of heart disease.

"With this release, we’ve moved the field of AI beyond just a narrow feature for echocardiography, to a complete decision-support solution for cardiologists and primary care providers,” said James Hare, CEO and co-founder of “Us2.v1 eliminates the manual workflows and lack of transparency from semi-automated, single measurement, black box AI approaches, creating a complete and fully automated patient report with editable annotations, conclusions and comparisons to international reference guidelines.”

Us2.v1 automated measurements include 2-D (cardiac volumes, all 4 chambers of the heart), M-mode (e.g. tricuspid annular plane systolic excursion), spectral Doppler (blood flow across all valves, both PW and CW measurements) and tissue Doppler; thus covering the vast majority of standard measurements for adult transthoracic echocardiography recommended by the American Society of Echocardiography (ASE), European Association of Cardiovascular Imaging, and British Society of Echocardiography.  

Fully automated Us2.v1 measurements were shown to be completely interchangeable with expert human measurements. The AI measurements also were completely reproducible for a given patient study, with image processing/analysis algorithm computation time of approximately 2 minutes per study, the vendor said.

Us2.v1 is designed to help to accelerate the diagnosis of diseases such as pulmonary hypertension and heart failure (HF). 

The company recently announced a partnership with EchoNous, maker of ultra-portable, AI-guided, point-of-care ultrasound (POCUS) tools. EchoNous is the maker of Kosmos, the only handheld ultra-mobile tool offering diagnostic grade imaging with Continuous-Wave (CW) Doppler capability.

Us2.v1 also automates the detection of pulmonary hypertension according to the European Society of Cardiology (ESC) / European Respiratory Society (ERS) guideline definition for echocardiographic detection of pulmonary hypertension. Pulmonary hypertension remains under-detected, leading to treatment delays and poor outcomes. 

Similarly, heart failure is a commonly missed diagnosis, particularly in general practices where access to echocardiography is currently limited. 

“AstraZeneca is excited to partner with because we believe it has the potential to transform the management of heart failure, bringing early access to echocardiography, including expert-level analyses, to primary care settings, the general community and even to patients’ home. Together, we look forward to helping improve care for patients with heart failure and keeping them out of hospital”, said Joris Silon, senior vice president, CVRM, bioPharmaceuticals business unit, AstraZeneca.

For more information:

Find more artificial intelligenece in cardiology content

Find more new cardiac ultrasound technology content

Related Content

Videos | Artificial Intelligence

Here are two examples of artificial intelligence (AI) driven pulmonary embolism (PE) response team apps featured by ...

Home January 13, 2022
Feature | Artificial Intelligence | By Dave Fornell, DAIC Editor

Artificial intelligence (AI) has found a unique niche to help automate the activation of acute care teams for pulmonary ...

Home December 09, 2021
News | Artificial Intelligence

December 2, 2021 — Artificial intelligence (AI) vendor DiA Imaging Analysis was featured in a recent study presented by ...

Home December 02, 2021
News | Artificial Intelligence

November 22, 2021 — Cardiologs, a leader in artificial intelligence (AI) cardiology diagnostics, announced the results ...

Home November 22, 2021
News | Artificial Intelligence

November 9, 2021 — Caption Health and Ultromics, developers of artificial intelligence (AI) to improve cardiac ...

Home November 09, 2021
News | Artificial Intelligence

September 27, 2021 — Zebra Medical Vision, the deep-learning medical imaging analytics company, announces its eighth U.S ...

Home September 27, 2021
Feature | Artificial Intelligence | By Dave Fornell, Editor

Artificial intelligence (AI) is growing in all areas of medicine and was the topic of several advanced technology ...

Home September 08, 2021
Webinar | Artificial Intelligence

Artificial intelligence is becoming best practice to support clinical decisions and help standardize echocardiography ...

Home August 12, 2021
News | Artificial Intelligence

July 21, 2021 — Artificial intelligence (AI) medical imaging vendors Viz.AI and Avicenna.AI have partnered to enable ...

Home July 21, 2021
Videos | Artificial Intelligence

Federico Asch, M.D., FASE, director of cardiovascular core labs, cardiovascular imaging, MedStar Health Research ...

Home July 01, 2021
Subscribe Now